Search Results - "Tesson, Pauline"

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer by Recondo, Gonzalo, Mezquita, Laura, Facchinetti, Francesco, Planchard, David, Gazzah, Anas, Bigot, Ludovic, Rizvi, Ahsan Z, Frias, Rosa L, Thiery, Jean Paul, Scoazec, Jean-Yves, Sourisseau, Tony, Howarth, Karen, Deas, Olivier, Samofalova, Dariia, Galissant, Justine, Tesson, Pauline, Braye, Floriane, Naltet, Charles, Lavaud, Pernelle, Mahjoubi, Linda, Abou Lovergne, Aurélie, Vassal, Gilles, Bahleda, Rastilav, Hollebecque, Antoine, Nicotra, Claudio, Ngo-Camus, Maud, Michiels, Stefan, Lacroix, Ludovic, Richon, Catherine, Auger, Nathalie, De Baere, Thierry, Tselikas, Lambros, Solary, Eric, Angevin, Eric, Eggermont, Alexander M, Andre, Fabrice, Massard, Christophe, Olaussen, Ken A, Soria, Jean-Charles, Besse, Benjamin, Friboulet, Luc

“…Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer…”
Get full text

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer by Recondo, Gonzalo, Mezquita, Laura, Facchinetti, Francesco, Planchard, David, Gazzah, Anas, Bigot, Ludovic, Rizvi, Ahsan, Frias, Rosa, Thiery, Jean Paul, Scoazec, Jean-Yves, Sourisseau, Tony, Howarth, Karen, Deas, Olivier, Samofalova, Dariia, Galissant, Justine, Tesson, Pauline, Braye, Floriane, Naltet, Charles, Lavaud, Pernelle, Mahjoubi, Linda, Abou Lovergne, Aurélie, Vassal, Gilles, Bahleda, Rastilav, Hollebecque, Antoine, Nicotra, Claudio, Ngo-Camus, Maud, Michiels, Stefan, Lacroix, Ludovic, Richon, Catherine, Auger, Nathalie, de Baere, Thierry, Tselikas, Lambros, Solary, Éric, Angevin, Eric, Eggermont, Alexander, Andre, Fabrice, Massard, Christophe, Olaussen, Ken, Soria, Jean-Charles, Besse, Benjamin, Friboulet, Luc

“…Abstract Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with…”
Get full text

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer by Recondo, Gonzalo, Mezquita, Laura, Facchinetti, Francesco, Planchard, David, Gazzah, Anas, Bigot, Ludovic, Rizvi, Ahsan, Frias, Rosa, Thiery, Jean Paul, Scoazec, Jean-Yves, Sourisseau, Tony, Howarth, Karen, Deas, Olivier, Samofalova, Dariia, Galissant, Justine, Tesson, Pauline, Braye, Floriane, Naltet, Charles, Lavaud, Pernelle, Mahjoubi, Linda, Abou Lovergne, Aurélie, Vassal, Gilles, Bahleda, Rastilav, Hollebecque, Antoine, Nicotra, Claudio, Ngo-Camus, Maud, Michiels, Stefan, Lacroix, Ludovic, Richon, Catherine, Auger, Nathalie, de Baere, Thierry, Tselikas, Lambros, Solary, Eric, Angevin, Eric, Eggermont, Alexander, Andre, Fabrice, Massard, Christophe, Olaussen, Ken, Soria, Jean-Charles, Besse, Benjamin, Friboulet, Luc

“…Abstract Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with…”
Get full text